Long Term Disease-Free Survivor in a Case of Multiple Myeloma Treated with Alpha Interferon, Melphalan and Prednisolone-A Case Report

自1979年後，α干擾素即廣泛地使用於治療多發性骨髓瘤之病人。我們亦曾以干擾素治療30個多發性骨髓瘤之病人，經治療後，並發現一長期無疾病存活者。病人為52歲之女性，於1990年4月診斷為第三期，G型免疫球蛋白，κ型之多發性骨髓瘤。病人接受傳統之melphalan/prednisolone (MP)治療，且在每一療程中之第3，4週各給予5MU/m^2 t. i. w.之干擾素共6次。每一療程為4週，一共給予12個療程。病人對治療之反應甚佳，於半年內，所有實驗室檢查均回復正常，包括骨髓活體切片，常規血液檢查，腎功能，放射線檢查，免疫球蛋白濃度，及β2-微球蛋白。因此經過12個干擾素／MP之療程及隨後之10個MP之療程後，病人停止所有化學治療，直到目前為止，病人仍在完全緩解中，其無疾病存活期為80個月以上。

關鍵字

α干擾素；化學治療；誘導治療；長期無疾病存活期；多發性骨髓瘤

並列摘要

Since 1979, α interferons (α IFNs) have been widely used for treating patients with multiple myeloma. We also performed a clinical study concerning the effect of α IFN therapy in 30 cases of multiple myeloma, and a long term survivor was noted in this study. She was a 52-yearold female with stage IIIA, IgG、κtype and previously untreated multiple myeloma. In addition to the classical treatment of melphalan/prednisolone (MP) for induction, α IFN (Intron A) was also given in-between the courses on the 3rd and 4th weeks of every course with 4-week as a course, totally for 12 courses. The dosage was 5 MU/m^2, t. i. w. for 2 weeks per course. The response was good and nearly all laboratory examinations returned to normal within half a year, including bone marrow biopsy, complete blood count, renal functions, X-rays, immunoglobulin levels and β2-microglobulin. Thus, after 12 courses of MP plus α IFN, and then 10 courses of MP alone, chemotherapy was stopped and she was in a complete remission state without evidence of multiple myeloma, the disease free survival time was ＞80 months.

並列關鍵字

α interferons ； chemotherapy ； induction therapy ； long-term disease-free survival ； multiple myeloma

國際替代計量

Long Term Disease-Free Survivor in a Case of Multiple Myeloma Treated with Alpha Interferon, Melphalan and Prednisolone-A Case Report

全文下載

主題瀏覽